高级检索
    刘馨屿, 任胜祥, 孙月丽. 疗效曙光初现,一线治疗前路坎坷——评免疫检测点抑制剂在HER2变异晚期非小细胞肺癌中的应用[J]. 循证医学, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002
    引用本文: 刘馨屿, 任胜祥, 孙月丽. 疗效曙光初现,一线治疗前路坎坷——评免疫检测点抑制剂在HER2变异晚期非小细胞肺癌中的应用[J]. 循证医学, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002
    shu
    LIU Xin-yu, REN Sheng-xiang, SUN Yue-li. Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002
    Citation: LIU Xin-yu, REN Sheng-xiang, SUN Yue-li. Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations[J]. Journal of Evidence-Based Medicine, 2022, 22(4): 198-201. DOI: 10.12019/j.issn.1671-5144.2022.04.002
    shu

    疗效曙光初现,一线治疗前路坎坷——评免疫检测点抑制剂在HER2变异晚期非小细胞肺癌中的应用

    Early Dawn of Curative Effect and Bumpy Road Ahead for First-Line Treatment: Evaluation on Application of Immune Checkpoint Inhibitor in Advanced Non-Small Cell Lung Cancer With HER2 Alterations

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回